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Abstract
Background: A major event in the post-meiotic development of male germ cells is the formation of the acrosome. This process
can be perturbed in C57BL/6 mice by administration of the small molecule miglustat (N-butyldeoxynojirimycin, NB-DNJ). The
miglustat-treated mice produce morphologically abnormal spermatozoa that lack acrosomes and are poorly motile. In C57BL/
6 mice, miglustat can be used to maintain long-term reversible infertility. In contrast, when miglustat was evaluated in normal
men, it did not affect spermatogenesis. To gain more insight into this species difference we have now evaluated the reproductive
effects of miglustat in rabbits, in multiple mouse strains and in interstrain hybrid mice.
Methods: Male mice of 18 inbred strains were administered miglustat orally or via miniosmotic pumps. Rabbits were given the
compound in their food. Fourth-generation interstrain hybrid mice, bred from C57BL/6 and FVB/N mice (which differ in their
response to miglustat), also received the drug. Data on fertility (natural mating), sperm motility and morphology, acrosome
status, and serum drug levels were collected.
Results: In rabbits the drug did not induce aberrations of sperm shape or motility, although the serum level of miglustat in
rabbits far exceeded the level in C57BL/6 mice (8.4 µM and 0.5 µM, respectively). In some strains of the Swiss and Castle lineages
of inbred mice miglustat did not cause infertility, severe morphological sperm aberrations or reduced sperm motility. In these
strains miglustat only had milder effects. However, miglustat strongly disturbed acrosome and sperm nucleus development in
AKR/J and BALB/c mice and in a number of C57BL/6-related strains. The consequences of drug administration in the interstrain
hybrid mice were highly variable. Judging by the number of grossly abnormal spermatozoa, these genetically heterogeneous mice
displayed a continuous range of intermediate responses, distinct from either of their parental strains.
Conclusion: The effects of miglustat on spermatogenesis in mice are strain-dependent, while in rabbits the drug is ineffective.
Evaluation of interstrain hybrid mice indicated that the sensitivity of spermatogenesis to miglustat is a quantitative trait. These
studies pave the way for identifying the genetic factors underlying the strain/species differences in the effect of miglustat.
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Background
In 2002 and 2003 miglustat was approved as an orphan
drug by the Federal Drug Administration (USA) and the
European Medicines Evaluation Agency, respectively, for
the treatment of type 1 Gaucher disease, a lysosomal gly-
cosphingolipid storage disorder. Miglustat can partially
inhibit the biosynthesis of glucosylceramide, by inhibit-
ing ceramide glucosyltransferase, and therefore can be
used to reduce the glucosphingolipid levels in cells [1].
Miglustat is tolerated in humans and at high doses in
mouse disease models [2,3]. Apart from the ceramide-spe-
cific glucosyltransferase miglustat inhibits in vitro a
number of other enzymes: α-glucosidases I and II, sucrase,
maltase, lysosomal glucocerebrosidase and the non-lyso-
somal glucosylceramidase [4-7]. The pharmacokinetics of
miglustat are relatively uncomplicated with no or very
limited metabolism, no protein binding and excretion
predominantly into the urine [8]. Renal clearance in
mouse and rat was greater than creatinine clearance, con-
sistent with active renal secretion not seen in rhesus mon-
key, dog or man [9].
Three weeks of oral administration of miglustat to male
C57BL/6 mice are sufficient to render them infertile [10].
The miglustat-induced infertility can be maintained for
several months without giving rise to overt adverse effects,
either physiological or behavioural [11]. Full fertility is
regained when the drug is withdrawn, even after 12
months of administration [10,11]. Spermatozoa released
from the epididymis of miglustat-treated C57BL/6 males
display a spectrum of abnormal head shapes. Acrosomal
antigens are mostly absent or display irregular patterns. In
addition, the mitochondria of these cells often have an
aberrant morphology and are arranged in relatively short
and wide mitochondrial sheaths. The motility of the
affected spermatozoa is severely impaired. ICSI experi-
ments with misshapen spermatozoa from treated C57BL/
6 mice showed that miglustat does affect sperm morphol-
ogy and physiology, but does not diminish the genetic
potential of spermatozoa [12].
The advanced clinical status of miglustat allowed the com-
pound to be evaluated for its reproductive effects in a
small number of normal healthy men. They received 100
mg of miglustat twice daily (on average 2 mg/kg/day) for
6 weeks, a similar dose as is given to Gaucher patients
[13]. During drug treatment and the following 12 weeks
various sperm parameters, including morphology and
capacity to undergo the acrosome reaction were meas-
ured. In the miglustat-treated men none of the reproduc-
tive features were significantly affected. The question is
now what underlies the difference in the response to
miglustat between men and male C57BL/6 mice. We have
assessed the effects of miglustat on sperm morphology,
particularly shape of nucleus and acrosome, in rabbits
and in 18 additional mouse strains. We have found large
differences in the sensitivity to the drug between mouse
strains, and also found the rabbit to be insensitive. This
suggests that the susceptibility to miglustat has a genetic
basis. We have therefore investigated its mode of inherit-
ance by analyzing the effects of miglustat on sperm mor-
phology in interstrain hybrid mice that were generated
from two strains of mice that differ profoundly in their
response to the drug.
Methods
Animals
Mice of the following inbred strains were purchased from
Harlan UK (Bicester, Oxfordshire, UK): A/J, BALB/c, C3H/
HeN, CBA/Ca, C57BL/6J, C57BL/10ScSn, DBA/2, FVB/N,
MRL/Mp, NZB and NZW. Male mice of the 129S1/SvImJ,
AKR/J, C57BR/J, C57L/J, C58, MA/MyJ, SM/J and YBR/J
strains were purchased from The Jackson Laboratory (Bar
Harbor, ME, USA). For the serum level experiments in
mice C57BL/6J and FVB/N mice were purchased from
Charles River Wiga GmbH (Sulzfeld, Germany).
Russenkaninchen rabbits strain (Crl:CHBB (HM)) were
from Charles River Wiga GmbH (Sulzfeld, Germany).
Male (2.4 – 3.2 kg, ca. 50 weeks) and female rabbits (2.6
– 3.0 kg,) were housed under 12 h light : 12 h dark (lights
on 7:00 h) at 22°C and had access to standard chow
(Ssniff, Soest, Germany) and water ad libitum., Only one
strain of rabbits was used because of the high costs of
miglustat. Also for this reason the Russenkaninchen strain
was used because of the relatively small size of the ani-
mals of this strain.
All animals were housed and sacrificed in accordance with
the UK Home Office Animals (Scientific Procedures) Act
1986 or in accordance with German legal requirements
dependent on the place where experiments have been per-
formed.
Fertility in rabbits
After passing a predosing phase of at least 2 weeks, 5 male
rabbits were fed 5, 15 or 50 mg/kg/day miglustat (Toronto
Research Chemicals, Toronto, Canada) for 8 weeks.
Miglustat was added to the standard chow and pressed
into pellets (Ssniff, Soest, Germany). Average drug uptake
was 5.2 ± 0.6 mg/kg/day in the 5 mg/kg/day group, 15.3
± 2.0 mg/kg/day in the 15 mg/kg/day group and 49.1 ±
3.8 mg/kg/day in the 50 mg/kg/day group. Control ani-
mals received standard chow without miglustat. Food
intake was not affected by the presence of miglustat in the
chow. Semen and blood samples were taken every 2
weeks. Blood was taken from the ear artery for measuring
miglustat levels with LC/MS. Semen samples were col-
lected according to [14]. Eight weeks after beginning the
treatment male rabbits of the control group and the 50Reproductive Biology and Endocrinology 2007, 5:1 http://www.rbej.com/content/5/1/1
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mg/kg/day group were caged together with one female
each for determination of fertility.
Quality of semen/spermatozoa from rabbits
Semen parameters determined were as follows: volume,
colour, pH, coagulation and sperm count. Spermatozoa
were subjected to computer-assisted sperm analysis
(CASA) (Hamilton Thorne Research, Beverly, MA, USA).
Percentage motile spermatozoa was estimated manually
by counting flagellating or non flagellating spermatozoa.
For the analysis by CASA 10 minutes after collection sper-
matozoa were diluted 20-times in medium (NaCl 97 mM,
KCl 3 mM, Na2HPO4 2.8 mM, MgCl2 4 mM, CaCl2 2 mM,
Na-pyruvate 0.2 mM, glucose 5 mM, HEPES 10 mM, BSA
6 g/l, NaHCO3 25 mM, lactate 32.8 mM) and approxi-
mately 10 µl of the suspension were placed in a 20 µm
deep sperm analysis chamber at 37°C (Standard Count
Analysis Chambers, Leja, Nieuw-Vennep, Netherlands).
Ten digitised film sequences were recorded (60 Hz). In
general, 100 sperm tracks from the recording were ana-
lysed by CASA (Animal Motility, version 12.2). The set-
tings used were as follows: frame rate: 60 Hz, number of
frames analysed: 30, minimum contrast: 50, minimum
size: 7, minimum number of detected data points for a
track: 10. For counting the number of spermatozoa with
aberrations air-dried sperm smears were made and stained
with PNA/DAPI (lectin PNA from Arachis hypogaea,
Alexa Fluor 488 conjugate, Molecular Probes, Oregon,
USA and 4',6-Diamidino-2-phenylindole Dihydrochlo-
ride, Sigma Aldrich, Germany diluted in PBS (GIBCO)).
Drug administration and mating tests in mice
Miglustat (gift from Oxford GlycoSciences, Abingdon,
UK/CellTech UK, Slough, Berkshire, UK, or purchased
from Toronto Research Chemicals, Toronto, Canada), as a
dry crystalline solid powder, was mixed thoroughly with
powdered mouse chow (expanded rat and mouse chow 1,
SDS, Witham, Essex, U.K.) and stored at room tempera-
ture. Male mice were fed powdered mouse chow with or
without miglustat for 5 weeks, at indicated doses. Alterna-
tively, the drug was administered via a mini-osmotic
pump (Model 2004, pump rate 0.22 – 0.26 µl/h, Alzet,
DURECT Corporation, California, USA) for 7 weeks. The
mice were 6 weeks old at the start of miglustat treatment.
Natural mating tests were performed as described by van
der Spoel et al [10]. Briefly, each male mouse was caged
with two or four female 10-week old C57BL/6 mice for
nine days, after which the male was removed and the
females were monitored for pregnancies and litter sizes.
Fluorescence microscopy of murine spermatozoa
Cauda epididymides were dissociated in M2 medium
(Sigma) with forceps. Smears of spermatozoa were pre-
pared as described by van der Spoel [10] and stained by
indirect immunofluorescence with monoclonal antibody
Mab18.6 [15], and Alexa488-conjugated goat anti-mouse
IgG (Molecular Probes). Propidium iodide (1 µg/ml) was
used as a nuclear stain. All antibodies were diluted in PBS
containing 0.5% (w/v) BSA and 0.15 M glycine. Nuclear
morphology and acrosomal staining were assessed using
a Zeiss Axioskop 2 plus microscope. Images were acquired
with a Zeiss 510 META confocal fluorescence instrument.
Western blotting
Mouse spermatozoa were released by gentle pressure from
caudae epididymides into ice-cold PBS containing Ca2+
and Mg2+, and washed twice in cold 10 mM Tris-HCl, pH
8.0, 1 mM EDTA, and taken up in Laemmli sample buffer.
Aliquots of lysed cells containing 5 µg protein were sepa-
rated by SDS-PAGE and transferred to Immobilon-P poly-
vinylidene fluoride membranes (Millipore, Watford, UK).
Blots were blocked in 10% milk powder in Tris-buffered
saline containing 0.05% Tween-20 (TBST), and incubated
with affinity-purified anti-bovine IAM38 antibodies [16]
(1:1000, overnight) or affinity-purified anti-VYK antibod-
ies [17] (1.2 ng/ml, overnight) in 2% milk powder in
TBST. Anti-VYK is an antiserum raised against a synthetic
peptide corresponding to residues 542–558 from murine
sp56 [17]. Anti-human cytochrome C oxidase subunit I
(A6403, Molecular Probes) was used (1:500, 2 hr) to ver-
ify equal loading. Blots were washed in TBST, incubated
with horse-radish peroxidase-conjugated anti-IgG anti-
bodies (Vector Laboratories, Peterborough, UK), washed,
and developed with a chemiluminescent substrate (ECL
Advance Western Blotting Detection Kit; Amersham,
Chalfont St.Giles, Buckinghamshire, UK).
Serum levels of miglustat
Serum level of miglustat was determined using liquid
chromatography and mass spectrometry. For sample
preparation acetonitrile (4-times the sample volume)
including an internal standard (1 µM N-(4-Chlorophe-
nyl)-2-[(4-pyridylmethyl)amino]benzamide) was added
to the serum sample and mixed thoroughly. Samples were
spun for 20 min at 4°C and > 2000 × g. The supernatant
was removed by rotary evaporation and reconstituted
with 20% acetonitrile solution. HPLC was performed on
a Varian Polaris C18-A column (particle size: 3 µm, col-
umn dimensions: 2 × 50 mm, Varian, Palo Alto, CA, USA)
at a flow rate of 0.3 ml/min. Eluents were 0.025%
NH3·H2O in water with an increasing acetonitrile gradi-
ent (5–95% over 3 min). Eluates were analysed by tandem
mass spectrometry.
Statistics
Quantitative data were statistically evaluated with Stu-
dent's t-test (comparison between two groups) or one-way
ANOVA with Tukey's post-hoc test (more than two
groups) using GRAPHPAD INSTAT version 3.0a for Mac-Reproductive Biology and Endocrinology 2007, 5:1 http://www.rbej.com/content/5/1/1
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intosh (GraphPad Software). Values were considered sta-
tistically significantly different when P < 0.05.
Results
Miglustat has no effect on fertility in male rabbits
Miglustat uptake did not affect the bodyweight and food
intake of the rabbits (data not shown). Each of the 5 male
rabbits in the control group and in the 50 mg/kg/day
group were mated to one female each after 8 weeks of
miglustat treatment. All of the 5 drug-treated rabbits were
fertile, comparable to the rabbits of the control group
(Table 1). Also, the litter size was not affected by miglustat
treatment (Table 1).
Sperm morphology and motility in rabbits
Coagulation, pH, colour, volume of semen and sperm
count remained unchanged at all the doses of miglustat
that have been tested (data not shown). Furthermore,
analysis of kinematic parameters by CASA did not reveal
any significant change (percentage motile spermatozoa in
Fig. 1A). In order to compare with the most prominent
effect of miglustat in male C57BL/6 mice, the number of
spermatozoa lacking intact acrosomes was counted using
a PNA/DAPI staining method (Fig. 2). The percentage of
spermatozoa that lacked intact acrosomes remained sta-
ble at approximately 20% in all doses for 8 weeks of treat-
ment (Fig. 1B).
Sperm morphology and motility in multiple mouse strains
In our previous studies [10-12], we used animals from the
C57BL/6 strain. Here, we administered the drug to males
of 18 additional strains other than C57BL/6. According to
the genealogy of inbred strains of mice [18], 11 of the
strains used were from the Swiss (FVB/N) and Castle
(129S1/SvImJ, A/J, AKR/J, BALB/c, C3H/HeN, CBA/Ca,
DBA/2, NZB, NZW and SM/J) families of strains, 6 from
the C57 lineage (C57BL/10, C57BR, C57L, C58, MA/My
and YBR), and one strain had a mixed background (MRL/
Mp). After treating these mice with 150 mg/kg/day miglu-
stat (a dose that renders C57BL/6 mice infertile), we
examined the acrosomal status and nuclear shape of their
cauda epididymal spermatozoa, by indirect immunofluo-
rescence with an anti-acrosomal monoclonal antibody
and a nuclear dye. The effects of the drug on sperm phe-
notype varied between mouse strains (Fig. 3). Because the
vast majority of C57BL/6 spermatozoa are without an
acrosome, and have a strongly abnormal (non-falciform)
nuclear morphology after miglustat administration [10],
we first scored the spermatozoa of the other strains for
these features. This analysis divided the mouse strains into
three groups. Firstly, five strains showed a major (>75%)
drug-induced reduction in the percentage of acrosome-
bearing spermatozoa and a high (>75%) increase in the
proportion of sperm cells with non-falciform sperm
nuclei (C57BL/6, C57BL/10, C57BR, C57L/J and C58/J,
Fig. 4A). Secondly, three strains had moderate (15–30%)
changes in both of these sperm parameters (BALB/c, AKR/
J and MA/MyJ, Fig. 4A). Finally, in most strains the drug
did not increase the proportion of spermatozoa with
grossly misshapen nuclei, while the two most-affected
strains of this third group (MRL/Mp and YBR) had a 20–
25% reduction in the appearance of acrosomes (Fig. 4A).
Thus the mice with the most perturbed sperm phenotype
were from 5 closely related strains of the C57 family. The
other two strains of this lineage were either moderately
(MA/MyJ) or slightly (YBR) affected, according to the cri-
teria applied.
Closer examination revealed that miglustat had a subtle,
but discernible impact on the sperm phenotype of the
Swiss/Castle strains. In many cases their spermatozoa did
stain with the anti-acrosomal antibody, but displayed an
irregular staining pattern, distinct from the typical cres-
cent morphology (Fig. 3E, J and 3K). In addition, the
nuclear morphology of the Swiss/Castle spermatozoa fre-
quently deviated from the normal shape, while remaining
falciform (i.e. flattened and to some extent curved, Fig. 3E,
J and 3K). Thus, after administering miglustat to males of
Table 1: Effects of miglustat administration on the fertility of male mice and rabbits as assessed by natural mating.
Species Strain Pregnancies/male Pups/litter
Control Miglustat Control Miglustat
Rabbit Russen-Kaninchen 1.0 ± 0.0 1.0 ± 0.0 7.0 ± 1.2 7.2 ± 1.5
Mouse C57BL/6 2.6 ± 0.9 0.0 ± 0.0* 6.7 ± 1.0 N/A
129S1/SvImJ 1.6 ± 0.5 1.6 ± 0.5 8.2 ± 0.6 8.9 ± 1.9
FVB/N 2.6 ± 1.5 2.2 ± 1.5 6.7 ± 1.6 6.0 ± 0.7
DBA/2 3.0 ± 0.7 2.8 ± 1.1 7.5 ± 0.8 6.3 ± 1.3
AKR/J 1.8 ± 0.4 1.4 ± 0.5 6.2 ± 2.3 3.6 ± 1.5
MA/MyJ 1.6 ± 0.5 0.8 ± 0.8 7.8 ± 0.8 3.8 ± 3.3
Data were obtained from 5 males/5 × 1 female (rabbits), from 5 males/5 × 4 females per strain (C57BL/6, FVB/N and DBA/2), or from 5 males/5 × 
2 females per strain (129S1/SvImJ, AKR/J and MA/MyJ). Miglustat administration to rabbits and mice was at 50 and 150 mg/kg/day, respectively. Data 
are expressed as means ± SD. Only the value marked with (*) is statistically different from control (P < 0.0002).Reproductive Biology and Endocrinology 2007, 5:1 http://www.rbej.com/content/5/1/1
Page 5 of 13
(page number not for citation purposes)
the 19 mouse strains, we also scored their sperm heads for
the normality of the acrosomal staining pattern, and
assessed the regularity of their nuclear morphology. In the
Swiss/Castle strains the decrease in the percentage of sper-
matozoa with a normal acrosome ranged from 16 to 69%,
while the percentage of cells with a typical falciform
nuclear morphology was between 8 and 57% lower (Fig.
4B).
The sperm phenotype of miglustat-treated FVB/N mice
was further compared with that of the C57BL/6 strain. To
complement the data on acrosome status obtained by
immunostaining with monoclonal Mab18.6, we used
western blotting to compare the levels of two other acro-
somal components, a protein present in the acrosomal
matrix (sp56, [17]) and a protein localized on the inner
acrosomal membrane (IAM38, [16]). After administra-
tion of miglustat to C57BL6 mice neither sp56 nor IAM38
was detectable in their spermatozoa, while in drug-treated
FVB/N mice the levels of these acrosomal proteins were
comparable to those of untreated animals of this strain
(Fig. 5). Thus the percentage of spermatozoa that stained
with Mab18.6 after miglustat treatment (2.9% for C57BL/
6 and 92% for FVB/N mice) correlated very well with the
levels of sp56 and IAM38 as measured by western blot-
ting.
Furthermore, after treatment of FVB/N mice with a higher
dose of miglustat (600 mg/kg/day) the appearance of
their spermatozoa was comparable to that seen at 150 mg/
Morphology of rabbit spermatozoa Figure 2
Morphology of rabbit spermatozoa. Smears of ejacu-
lated spermatozoa were air-dried and stained with PNA/
DAPI. A. Spermatozoa from control rabbits. B. Spermatozoa 
from rabbits treated with 50 mg/kg/day miglustat for 8 
weeks. Bar = 20 µm.
Sperm motility (%) and morphology in rabbits Figure 1
Sperm motility (%) and morphology in rabbits. A. 
Spermatozoa were released in medium and percentage 
motile spermatozoa was estimated by counting flagellating or 
non flagellating spermatozoa. B. For assessment of morphol-
ogy, a smear was air-dried on a slide and stained with PNA 
and DAPI and counted manually for abnormal sperm heads. 
Data are presented as the mean ± SD of percentage motile 
spermatozoa for 5 males and as the mean ± SD of percent-
age abnormal spermatozoa. Nuclear morphology and acro-
somal staining were assessed by examining 100 spermatozoa 
per rabbit.Reproductive Biology and Endocrinology 2007, 5:1 http://www.rbej.com/content/5/1/1
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Effects of miglustat on morphology of spermatozoa from various mouse strains Figure 3
Effects of miglustat on morphology of spermatozoa from various mouse strains. Acrosomal and nuclear morphol-
ogy of cauda epididymal spermatozoa from (A, B, C, G, H and I) control and (D, E, F, J, K and L) miglustat-treated mice from 
inbred mouse strains, (A and D) C57BR, (B and E) FVB/N, (C and F) BALB/c, (G and J) DBA/2, (H and K) AKR/J and (I and L) MA/
MyJ. Acrosomes were stained with the monoclonal antibody Mab18.6 (green) and nuclei with propidium iodide (red). Drug 
administration was at 150 mg/kg/day. Bar = 10 µm.Reproductive Biology and Endocrinology 2007, 5:1 http://www.rbej.com/content/5/1/1
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Quantitation of effects of miglustat on morphology of spermatozoa from inbred mouse strains and interstrain hybrid mice Figure 4
Quantitation of effects of miglustat on morphology of spermatozoa from inbred mouse strains and interstrain 
hybrid mice. Effects of miglustat administration on morphological features of cauda epididymal spermatozoa from (A and B) 
mice of various inbred strains (n = 2–3 per strain) and from (C and D) fourth-generation C57BL/6 × FVB/N hybrid mice. In (A 
and C) spermatozoa were scored for possession of an acrosome (present/absent), irrespective of acrosomal staining pattern, 
and for possession of a grossly abnormal non-falciform nucleus. In (B and D) spermatozoa were scored for acrosomal staining 
pattern (normal/abnormal), and for the normality of their nuclear morphology. Falciform nuclei (flat and curved) that deviated 
from the typical shape of spermatozoa from untreated mice were score as abnormal. In (C and D) data are presented from the 
hybrid mice that were most affected by miglustat, and from a representative number of hybrid mice that showed a lesser 
response. Each datapoint in (A and B) expresses the difference between the average score of drug-treated mice from one 
inbred strain and the average score of control mice of the same strain. Each datapoint in (C and D) expresses the difference 
between the score of one drug-treated hybrid mouse and the average score of untreated FVB/N mice. Data points were fitted 
by linear regression; the corresponding trend lines are displayed in grey (correlation coefficients in A, B, C and D were 0.97, 
0.79, 0.98 and 0.84, respectively). Miglustat administration was at 150 mg/kg/day, except SM/J mice (15 mg/kg/day). At least 200 
spermatozoa per mouse were scored for nuclear morphology and acrosomal staining.Reproductive Biology and Endocrinology 2007, 5:1 http://www.rbej.com/content/5/1/1
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kg/day (Fig. 6B and Fig. 3E, respectively). Both at 150 and
600 mg/kg/day the drug-induced abnormalities were lim-
ited to mild nuclear and acrosomal irregularities. The per-
centages of spermatozoa with these defects did not differ
significantly between the lower and higher drug dose
(data not shown).
Miglustat has a variable impact on the fertility of male 
mice
To establish whether the miglustat-induced alterations in
the sperm phenotypes from the Swiss/Castle mice were
relevant for their fertility, drug-treated males (150 mg/kg/
day) from a number of these strains were assessed in a nat-
ural mating test. The strains used in this test were selected
to represent the extent of variation in the responses to
miglustat among the Swiss/Castle strains (Fig. 4B), from
slight (129S1/SvlmJ), moderate (FVB/N), to more pro-
foundly affected (AKR/J and DBA/2J). In addition, the
moderately impacted C57 strain MA/MyJ (Fig. 4A) was
also tested. In contrast to miglustat-treated C57BL/6 mice,
the fertility of the 129S1/SvlmJ, FVB/N and DBA/2J males
was unchanged (Table 1). Miglustat treatment reduced the
size of litters sired by the AKR/J and MA/MyJ males, but
this was not statistically significant (Table 1). Thus the
considerable increase (69%) in the percentage of sperma-
tozoa with a misshapen acrosome, in combination with
moderately more (37%) spermatozoa with an abnormal
falciform nuclear morphology, did not impair the fertility
or size of litters sired by male mice, as seen in the DBA/2J
strain. Similarly, with a 29% increase in spermatozoa
without an acrosome and 16% of sperm cells with a
severely abnormal (non-falciform) nuclear shape, the
AKR/J were not infertile. Therefore, whereas miglustat
affected the sperm phenotype in many mouse strains (Fig.
3 and Fig. 4A and 4B), this did not result in infertility in
most cases (Table 1). Clearly, drug-induced infertility (as
seen in C57BL/6 mice) was associated with a major
absence of acrosomes and high proportion of grossly
aberrant sperm nuclei.
Miglustat levels in serum in mouse strains and rabbits
The variation in the effects of miglustat among rabbits and
different mouse strains could be due to unequal serum
levels, which, in turn, may be a reflection of variability in
the rate of renal drug excretion. Therefore, miglustat levels
in serum were determined by LC/MS. Although adminis-
tration of 15 mg/kg/day miglustat s.c. via mini osmotic
pumps rendered C57BL/6 but not FVB/N mice infertile,
Effects of miglustat on acrosomal proteins as detected by western blotting Figure 5
Effects of miglustat on acrosomal proteins as detected by western blotting. The impact of miglustat administration 
on the levels of the acrosomal proteins sp56 and IAM38 was assessed both in C57BL/6 and in FVB/N mice. Replicate western 
blots were prepared with lysates of epididymal spermatozoa and probed with antibodies against sp56, IAM38, or cytochrome 
C oxidase subunit I. Miglustat treatment was at 15 mg/kg/day.Reproductive Biology and Endocrinology 2007, 5:1 http://www.rbej.com/content/5/1/1
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Effects of miglustat on morphology of spermatozoa from interstrain hybrid mice Figure 6
Effects of miglustat on morphology of spermatozoa from interstrain hybrid mice. Acrosomal and nuclear morphol-
ogy of cauda epididymal spermatozoa from miglustat-treated (A) C57BL/6 (15 mg/kg/day) and (B) FVB/N mice (600 mg/kg/day), 
and from (C, D, E and F) fourth-generation C57BL/6 × FVB/N hybrid mice (15 mg/kg/day). These drug-treated hybrid mice dif-
fered in their proportion of non-falciform acrosome-less spermatozoa. This proportion increases from C to F. Acrosomes 
were stained with the monoclonal antibody Mab18.6 (green), and nuclei with propidium iodide (red). Bar = 10 µm.Reproductive Biology and Endocrinology 2007, 5:1 http://www.rbej.com/content/5/1/1
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the drug treatment generated a similar miglustat level in
the serum of C57BL/6 and in FVB/N mice (Table 2). In
rabbits the serum level was determined at the highest dose
used (50 mg/kg/day), at which the animals were fertile.
The serum level found in rabbits exceeded the level in
C57BL/6 mice 17-fold (Table 2). Thus, the serum concen-
tration of miglustat did not correlate with the fertility sta-
tus of the mice and rabbits.
Genetic basis of the susceptibility to miglustat
Having observed that the consequences of miglustat
administration varied between mouse strains, we rea-
soned that the differential response to the drug possibly
has a genetic basis. Therefore, we generated small num-
bers of second-generation interstrain hybrid mice from
the C57BL/6 and FVB/N strains. Eight F2 hybrids were
obtained from C57BL/6 males and FVB/N females, and 6
F2 hybrids were bred from FVB/N males and C57BL/6
females. In each of these two groups of F2 hybrid mice
one animal displayed the C57 drug-induced sperm phe-
notype and one animal had a phenotype that was inter-
mediate between the two original strains. The remainder
of the F2 hybrids responded to miglustat administration
in the same way as FVB/N mice (data not shown). Thus,
the high sensitivity to the imino sugar (resulting in the
production of acrosome-less non-falciform abnormal
spermatozoa) had both a maternal and a paternal inherit-
ance.
To further investigate the genetic basis of the imino sugar
responsiveness, we generated over 200 fourth-generation
hybrid mice from C57BL/6 males and FVB/N females.
These animals were treated with 15 mg/kg/day of miglus-
tat, and their epididymal spermatozoa were examined
and scored for the acrosomal and nuclear parameters
described above. Over 70% of the hybrid mice responded
to miglustat administration in a similar fashion as the
FVB/N mice, while only 3 of them behaved like a C57BL/
6 mouse. However, the remainder of the interstrain
hybrid mice showed a range of effects, from low to very
high percentages of non-falciform dysmorphic spermato-
zoa without acrosomes (Fig. 4C and Fig. 6C–F). Among
the hybrid mice were a number of animals with an inter-
mediate drug-induced phenotype (between 30 and 70%
reduction in acrosome presence, and between 20 and
70% increase in non-falciform abnormal nuclei, Fig. 4C).
Such a phenotype was not seen in any of the inbred
mouse strains after miglustat treatment (Fig. 4C vs. 4A).
Similar to the inbred strains, the epididymal spermatozoa
from the interstrain hybrids also displayed irregular acro-
somal structures and atypical falciform nuclei (Fig. 4D
and Fig. 6C–F).
Discussion
We have evaluated the reproductive effects of miglustat in
rabbits and in various strains of the C57 and Swiss/Castle
lineages of inbred mice. In contrast to miglustat-treated
C57 mice, fertility was not affected in the other mouse
strains and the rabbit strain that have been studied. The
contraceptive effect of miglustat seems therefore to be spe-
cific to the C57 strains.
In mice, the most profound effects of miglustat on the
shape of sperm nuclei and on the presence of acrosomes
on sperm heads were found in strains of the C57 family
(the majority of sperm nuclei non-falciform dysmorphic,
most spermatozoa without an acrosome), correlating
closely with the contraceptive action in C57BL/6 mice. A
milder category of sperm aberrations after miglustat treat-
ment was found in most strains of the Swiss/Castle line-
ages (low to moderate frequencies of mild morphological
abnormalities of falciform nuclei, most spermatozoa with
acrosomes, a fraction of them with imperfections or aber-
rations). Clearly, this type of spermatozoal abnormalities
is not of a severity that impairs the fertility of the animals,
as the drug-treated 129S1/SvImJ, FVB/N and DBA/2 males
had normal pregnancy rates in mating tests. We also
observed an intermediate level of sperm aberrations, in
miglustat-treated BALB/c, Ma/MyJ and AKR/J mice (a
minority of spermatozoa with non-falciform nuclei, with-
out acrosomes). This level of miglustat-induced spermato-
zoal abnormalities was not associated with infertility in
Table 2: Serum levels of miglustat in selected strains/species.
Species Mouse Rabbit
Strain C57BL/6 FVB/N Russen-kaninchen
Dose (mg/kg/day) 15 15 50
Serum level (µM) 0.49 ± 0.26 0.61 ± 0.17 8.39 ± 5.38
Fertility (fertile/total) 0/6 6/6 5/5
Miglustat was administered to both strains of mice via a miniosmotic pump and miglustat was given to rabbits via their food. Male mice were caged 
with 2 single females subsequently at week 5 and 6. Male rabbits were mated to one female each. Serum levels were determined from blood serum 
by means of LC/MS. Data are expressed as means ± SD.Reproductive Biology and Endocrinology 2007, 5:1 http://www.rbej.com/content/5/1/1
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the drug-treated Ma/MyJ and AKR/J mice. Finally, in one
rabbit strain miglustat administration did not result in
any observable changes in sperm phenotype.
What therefore underlies the differences in the effect of
miglustat between various mouse strains and between
species? One possibility is that the males of the Swiss/Cas-
tle strains and the rabbits could be less sensitive to the
drug. That would imply that a higher dose of miglustat
should result in a more severe phenotype in these strains
and in rabbits. We have investigated this in FVB/N mice,
by administering 150 and 600 mg/kg/day of miglustat.
We found the same effects in males of this strain at both
doses of the drug, not a C57-style sperm phenotype at the
higher dose. This suggests that it is unlikely that the dis-
parity in the imino sugar-response between Swiss/Castle
and C57 strains is due to a lower drug sensitivity of the
former strains, rather that the consequences of miglustat
in these strains are qualitatively different. Secondly, the
differences in reproductive outcome of miglustat treat-
ment observed between mouse strains and species could
be due to differential pharmacokinetics of the imino sugar
(e.g. variations in the rate of renal excretion), resulting in
different serum concentrations when administered at the
same dose of drug. Clearly, this was not the case as serum
levels were the same or even higher in the non-responding
FVB/N strain (0.6 µM) and in rabbits (8.4 µM), compared
to the highly responding C57BL/6 mice (0.5 µM). In men,
the miglustat level was >4 µM in serum and 8 µM in sem-
inal plasma [13]
Recently, it has been speculated that the primary target of
miglustat is β-glucosidase 2 (GBA2), because a deficiency
in GBA2 results in the production of abnormal spermato-
zoa [19,20], and because GBA2 can be inhibited by com-
pounds that are chemically similar to miglustat [21]. In
addition, GBA2 has been identified as being responsible
for the non-lysosomal glucosylceramidase activity [22],
which can be inhibited by miglustat [5]. To date it has not
been reported whether miglustat inhibits GBA2 in vivo.
Nevertheless, it is conceivable that the interaction of
miglustat with its primary target (possibly GBA2) is the
first step in a cascade of events that brings about the dra-
matic effects of miglustat on spermiogenesis in C57
strains. This cascade including downstream components
needs to be considered when investigating the basis of the
diversity in the reproductive consequences of miglustat in
the various mouse strains and between species. Possibly,
the direct effect of miglustat on the primary drug target, or
its indirect impact on a component of the downstream
pathway is strain/species-dependent. Studies are currently
in progress focusing on the in vivo biochemical conse-
quences of miglustat administration, with particular
emphasis on the glycosphingolipid pathway.
Our studies with the C57BL/6 × FVB/N interstrain hybrid
mice provide an indication of the genetics of the sensitiv-
ity to miglustat. Whereas the majority of the fourth-gener-
ation hybrid mice responded to miglustat in a similar
fashion as FVB/N mice, only very few displayed the
C57BL/6 phenotype. About one-third of the interstrain
hybrid mice simultaneously produced spermatozoa with
an acrosome and a falciform nuclear shape, as well as
acrosome-deficient spermatozoa with grossly aberrant
nuclei. Remarkably, these two types of spermatozoa were
produced in various proportions that had not been seen
in either of the parental strains. Clearly, the sensitivity of
spermatogenesis for miglustat is not inherited in a Mende-
lian fashion. Rather, the reproductive impact of miglustat,
expressed as the percentage of acrosome-less spermatozoa
with a non-falciform nuclear shape, appears to be a quan-
titative trait. It is therefore likely that multiple genes con-
tribute to the sensitivity of spermatogenesis to miglustat.
Similar observations have been made in the study of the
susceptibility to lung injury by ozone. Mice of the A/J
strain are susceptible in this respect, while C57BL/6 mice
are resistant [23]. Recombinant inbred strains generated
from these two strains displayed many intermediate levels
of ozone susceptibility, in a continuous range, indicating
a multigenic trait [24].
The observation that the effect of a drug, a toxicant, or
gene ablation is dependent on genetic background is not
uncommon, and has been seen in many fields, including
reproductive biology. For example, low-dose cadmium
causes necrosis in the seminiferous epithelium in DBA/2,
but not in C57BL/6 mice [25]. The resistance to this heavy
metal is an autosomal recessive trait that is inherited in a
Mendelian fashion [26]. In three distinct lines of knock-
out mice, the deficiency results in male sterility in a 129/
Sv background, but not in mixed C57BL/6 × 129/Sv ani-
mals [27-29]. Germ cell depletion 2 (gcd2), a chemically
induced recessive mutation, affects almost all males when
homozygously present in a CAST/Ei mice, but only a
minority of mice against a C57BL/6 background [30].
Also, the male infertility, seen in the leptin-deficient ob/ob
mice that are on a C57BL/6 background, is rescued when
the deficiency is bred into the BALB/c strain [31,32]. In
addition, experimentally induced cryptorchidism has a
negative impact on spermatogenesis in most strains, but
not in AKR/N and MRL/Mp mice [33].
It will be interesting to determine which genetic factors
determine the susceptibility to miglustat, not the least
because the capacity of the drug to specifically interfere in
acrosome biogenesis is exceptional (even when manifest
in only a limited number of mouse strains). Various
approaches can be followed in this endeavour, starting
with a genomic evaluation of the panels of the C57BL/6 ×
FVB/N interstrain hybrid mice and of the 19 mouseReproductive Biology and Endocrinology 2007, 5:1 http://www.rbej.com/content/5/1/1
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strains, in which the compound has been tested. These
studies are currently in progress.
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